SE457933B - Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion - Google Patents
Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostionInfo
- Publication number
- SE457933B SE457933B SE8702784A SE8702784A SE457933B SE 457933 B SE457933 B SE 457933B SE 8702784 A SE8702784 A SE 8702784A SE 8702784 A SE8702784 A SE 8702784A SE 457933 B SE457933 B SE 457933B
- Authority
- SE
- Sweden
- Prior art keywords
- weight
- monoglyceride
- phosphatidylcholine
- composition
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 150000002632 lipids Chemical class 0.000 title claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 title description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000006185 dispersion Substances 0.000 claims abstract description 25
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 235000013311 vegetables Nutrition 0.000 claims abstract description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 10
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 8
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 8
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 6
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 239000010775 animal oil Substances 0.000 claims description 10
- 239000008158 vegetable oil Substances 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 210000004072 lung Anatomy 0.000 claims description 7
- 210000000683 abdominal cavity Anatomy 0.000 claims description 5
- 210000004379 membrane Anatomy 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 claims description 5
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 210000001156 gastric mucosa Anatomy 0.000 claims description 4
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- 229940074096 monoolein Drugs 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- USPSDZQQNLMVMK-UHFFFAOYSA-N 1-Monolinolein Natural products CCCCCC=CC=CCCCCCCCC(=O)OCC(O)CO USPSDZQQNLMVMK-UHFFFAOYSA-N 0.000 claims 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims 2
- 240000006240 Linum usitatissimum Species 0.000 claims 1
- 235000004431 Linum usitatissimum Nutrition 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 210000004303 peritoneum Anatomy 0.000 abstract description 2
- 230000003450 growing effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000012266 salt solution Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010086613 Streptodornase and Streptokinase Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- -1 hydrogen ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011251 protective drug Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8702784A SE457933B (sv) | 1987-07-06 | 1987-07-06 | Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion |
| EP88850222A EP0299937A1 (en) | 1987-07-06 | 1988-06-21 | A composition based on phosphatidylcholine and medical uses thereof |
| JP63166650A JPS6461421A (en) | 1987-07-06 | 1988-07-04 | Composition based on phosphatidyl choline and medicinal use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8702784A SE457933B (sv) | 1987-07-06 | 1987-07-06 | Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8702784D0 SE8702784D0 (sv) | 1987-07-06 |
| SE8702784L SE8702784L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-01-07 |
| SE457933B true SE457933B (sv) | 1989-02-13 |
Family
ID=20369073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8702784A SE457933B (sv) | 1987-07-06 | 1987-07-06 | Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion |
Country Status (3)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4005711C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1990-02-23 | 1991-06-13 | A. Nattermann & Cie Gmbh, 5000 Koeln, De | |
| FR2670365B1 (fr) * | 1990-12-18 | 1993-12-24 | Eurial | Boisson lactee et procede pour sa preparation. |
| FR2714621B1 (fr) * | 1994-01-06 | 1996-02-23 | Centre Nat Rech Scient | Procédé de préparation de liposomes sans utilisation de solvant organique. |
| AU702030B2 (en) * | 1995-10-12 | 1999-02-11 | Gs Development Ab | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
| AU740832B2 (en) * | 1998-05-13 | 2001-11-15 | Innovata Limited | Dextrin-containing composition for preventing surgical adhesions |
| CN1368874A (zh) * | 1999-08-06 | 2002-09-11 | 马克斯－德尔布吕克分子医学研究所 | 可植入的生物活性物质储存体 |
| GB0200704D0 (en) * | 2002-01-14 | 2002-02-27 | Britannia Pharmaceuticals Ltd | Use of phospholipids in peritoneal dialysis |
| AU2003266884A1 (en) * | 2002-09-16 | 2004-04-30 | Vasogen Ireland Limited | Accelerating recovery from trauma |
| WO2008084864A1 (ja) * | 2007-01-11 | 2008-07-17 | Nisshin Pharma Inc. | カプサイシン受容体活性化剤及びそれを噴霧する装置 |
| WO2012020279A1 (en) * | 2010-08-13 | 2012-02-16 | Compagnie Gervais Danone | Product for the upper gastric sphere |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55153713A (en) * | 1979-05-02 | 1980-11-29 | Kureha Chem Ind Co Ltd | Pharmaceutical preparation of ribosome containing active substance |
| DE3028074C2 (de) * | 1980-07-22 | 1983-12-08 | Kurt Kampffmeyer Mühlenvereinigung KG, 2000 Hamburg | Verfahren zur Herstellung eines lecithinhaltigen Produktes |
| DE3470277D1 (en) * | 1984-01-11 | 1988-05-11 | Von Mletzko Armin | Dietetic composition |
| IT1176916B (it) * | 1984-10-10 | 1987-08-18 | Elvira Pistolesi | Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica |
-
1987
- 1987-07-06 SE SE8702784A patent/SE457933B/sv not_active IP Right Cessation
-
1988
- 1988-06-21 EP EP88850222A patent/EP0299937A1/en not_active Withdrawn
- 1988-07-04 JP JP63166650A patent/JPS6461421A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0299937A1 (en) | 1989-01-18 |
| SE8702784D0 (sv) | 1987-07-06 |
| JPS6461421A (en) | 1989-03-08 |
| SE8702784L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8536232B2 (en) | Omega-3 diglyceride emulsions | |
| ES2324526T3 (es) | Emulsiones isotonicas de lipidos. | |
| JP3387498B2 (ja) | 燐脂質 | |
| PT2429317T (pt) | Composições ricas em ácidos gordos ómega-3 com um teor baixo de ácido fitânico | |
| EP3280274B1 (en) | Nutrition with large lipid globules comprising vegetable fat coated with milk phospholipids for improving gastric emptying | |
| CA2838312C (en) | Therapeutic application of parenteral krill oil | |
| ES2189891T5 (es) | Emulsiones de lipidos optimizadas para la hidrolisis y uso de las mismas. | |
| JPH09508413A (ja) | 水中油エマルジョン | |
| WO2008120249A1 (en) | Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use | |
| SE457933B (sv) | Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion | |
| WO2007059431A1 (en) | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs | |
| WO2012150839A2 (ko) | 포스파티딜세린의 마이크로캡슐화 방법 | |
| CN1278177A (zh) | 血管生成促进剂 | |
| JPH03101622A (ja) | 肝炎予防治療剤 | |
| US10300035B2 (en) | Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration | |
| US20100016269A1 (en) | Composition of plant sterol and phosphatidylcholine and method for producing the same | |
| CN104771354B (zh) | 用于眼用的基于非极性和极性脂质的药物制剂 | |
| HUP9903426A2 (hu) | Optimalizált hidrolízisű lipid emulziók és ezek gyógyszerként történő alkalmazása | |
| JPS63166425A (ja) | 耐塩性界面活性剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8702784-3 Effective date: 19900703 Format of ref document f/p: F |